Page 65 - Read Online

Zerehpooshnesfchi et al. Metab Target Organ Damage. 2025;5:15 https://dx.doi.org/10.20517/mtod.2025.04 Page 11 of 11

51. Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533-40.
DOI PubMed
52. Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission.
Lancet Gastroenterol Hepatol. 2020;5:167-228. DOI PubMed PMC
53. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C
endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237-43. DOI PubMed
54. van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes
in patients with chronic hepatitis B. JHEP Rep. 2021;3:100350. DOI PubMed PMC
55. Manzano-Nunez R, Rivera-Esteban J, Navarro J, et al. Uncovering the NAFLD burden in people living with HIV from high- and
middle-income nations: a meta-analysis with a data gap from Subsaharan Africa. J Int AIDS Soc. 2023;26:e26072. DOI PubMed
PMC
56. Díaz LA, Ayares G, Arnold J, et al. Liver diseases in latin america: current status, unmet needs, and opportunities for improvement.
Curr Treat Options Gastroenterol. 2022;20:261-78. DOI PubMed PMC
57. Müller L. Integrated approaches in chronic disease management: a new model for internal medicine. Arch Med. 2025;17:001-2.
Available from: https://www.itmedicalteam.pl/articles/integrated-approaches-in-chronic-disease-management-a-new-model-for-
internal-medicine.pdf [Last accessed on 27 Mar 2025].
58. Okpujie V, Tobalesi O, Uwumiro F, et al. The influence of insulin resistance on outcomes in hospitalizations for alcohol-related liver
disease: a nationwide study. Cureus. 2023;15:e42964. DOI PubMed PMC
59. Kernick D, Chew-Graham CA, O’Flynn N. Clinical assessment and management of multimorbidity: NICE guideline. Br J Gen Pract.
2017;67:235-6. DOI PubMed PMC
60. Fernandez CJ, Alkhalifah M, Afsar H, Pappachan JM. Metabolic dysfunction-associated fatty liver disease and chronic viral hepatitis:
the interlink. Pathogens. 2024;13:68. DOI PubMed PMC
61. Zhang H, Targher G, Byrne CD, et al; MAFLD ICD-11 coding collaborators. A global survey on the use of the international
classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024;18:1178-201. DOI PubMed
62. Zhou XD, Lonardo A, Pan CQ, Shapiro MD, Zheng MH; WMU MAFLD Clinical Research Working Group. Clinical features and
long-term outcomes of patients diagnosed with MASLD, MAFLD, or both. J Hepatol. 2024;81:e157-9. DOI PubMed
63. Åberg F, Byrne CD, Pirola CJ, Männistö V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological
impact on liver disease. J Hepatol. 2023;78:191-206. DOI PubMed
64. Pan Z, Khatry MA, Yu ML, et al. MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.
Ther Adv Endocrinol Metab. 2024;15:20420188241252543. DOI PubMed PMC
65. Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better
than MASLD. Hepatol Int. 2024;18:964-72. DOI PubMed
66. Pan Z, Eslam M; panel of collaborators. The MASLD criteria overlook a number of adolescent patients with severe steatosis. J
Hepatol. 2024;81:e80-1. DOI PubMed
67. Pan Z, Shiha G, Esmat G, Méndez-Sánchez N, Eslam M. MAFLD predicts cardiovascular disease risk better than MASLD. Liver Int.
2024;44:1567-74. DOI PubMed
68. Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan JG, Eslam M. MAFLD criteria are better than MASLD criteria at predicting the
risk of chronic kidney disease. Ann Hepatol. 2024;29:101512. DOI PubMed
69. Hoang T, Lee J, Kim BH, Cho Y, Kim J. Evaluation of nomenclature of fatty liver disease in association with hepatocellular
carcinoma: a 14.5-year cohort study in Korea. Cancer Res Treat. 2025;Epub ahead of print. DOI PubMed
70. Vaz K, Kemp W, Majeed A, et al. MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with
components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study. Hepatol Int. 2024;Epub ahead of print.
DOI PubMed
71. Jiang M, Pan Z, George J, Eslam M. Clinical features and mortality outcomes of patients with MASLD only compared to those with
MAFLD and MASLD. Hepatol Int. 2024;18:1731-9. DOI PubMed
72. Pan Z, Yilmaz Y, Al-Busafi SA, Eslam M. The MAFLD definition identifies three homogenous groups of patients. Liver Int.
2024;44:3287-9. DOI PubMed
73. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol. 2024;80:e62-4. DOI
PubMed
74. Lonardo A, Bril F, Caldwell SH, et al. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new
MASLD nomenclature. J Hepatol. 2024;80:e192-4. DOI PubMed